INTRODUCTION
Protein kinase C (PKC) is a serine/threonine kinase important in signal transduction; activation of PKC is dependent on Ca2+ and phospholipids (Nishizuka, 1989) . Tumour-promoting phorbol esters can activate PKC in vitro and in vivo (Castagna et al., 1982; MacFarlane, 1986; Hornbeck et al., 1988) . Among protein substrates phosphorylated by PKC are nuclear proteins (McFarlane, 1986) suggestive of PKC activity in the nucleus. Additional evidence for the presence of PKC in the nucleus was gained from studies on subcellular distribution of PKC by immunofluorescence, Western blots and enzymic activity; importantly, the amount ofPKC in the nuclear membrane increased several-fold in response to treatment with phorbol 12-myristate 13-acetate (PMA), indicative of a nuclear translocation of PKC (Halsey et al., 1987; Leach et al., 1989) .
Topoisomerase I is a nuclear enzyme that catalyses DNA topological changes essential in DNA transcription and recombination (Wang, 1985; Liu, 1989) . In earlier studies we and others have reported that topoisomerase I can be regulated by phosphorylation with nuclear NII kinase (a type II casein kinase): dephosphorylation decreased or abolished topoisomerase I activity, and phosphorylation with NII kinase re-activated topoisomerase I (Durban et al., 1983; 1985; Kaiserman et al., 1988) .
More recent studies have demonstrated a potential second regulatory phosphorylation pathway for topoisomerase I mediated by PKC. Topoisomerase I activity was increased by phosphorylation with PKC in vitro (Pommier et al., 1990; Samuels et al., 1989 ).
The present study shows that human topoisomerase I is phosphorylated in vitro by PKC with high affinity. Phosphorylation of topoisomerase I in HL-60 cells in vivo occurs rapidly within 20 min of PMA administration, suggesting that PKC controls topoisomerase I phosphorylation in vivo.
MATERIALS AND METHODS Purfflcation of topoisomerase I
Topoisomerase I was purified as described by Durban et al. (1981) . Briefly, HeLa cells were washed with RSB buffer (10 mM Topoisomerase I phosphorylation was stimulated 3-fold in HL-60 cells exposed to the tumour promoter phorbol 12-myristate 13-acetate. The results suggest that topoisomerase I phosphorylation in HL-60 cells is indirectly controlled by PKC.
Tris/HCl, pH 7.2, 10 mM NaCl, 1.5 mM MgCl2), resuspended in RSB buffer containing 0.5 % Nonidet P-40, homogenized in a Dounce homogenizer and centrifuged. Nuclei were lysed in 10 mM Tris/HCl, pH 8.0, and chromatin was extracted with 0.35 M NaCl. Each buffer contained 1 mM phenylmethanesulphonyl fluoride (PMSF) (Sigma) and 0.1 ml/I aprotinin (Sigma) as protease inhibitors. The extracted material was centrifuged overnight at 1000OOg and the supernatant was precipitated with (NH4)2SO4. The 50-85 %-satd. fraction was dissolved in 1 mM dithiothreitol (DTT)/l mM PMSF/50 mM potassium phosphate buffer, pH 7.3, and dialysed against the same buffer. Calcium phosphate gel (17 mg/ml of water) was added to the dialysed fraction. The calcium phosphate gel was washed with the above buffer and then eluted consecutively with 0.15 M, 0.35 M and 0.8 M phosphate buffer, pH 7.3, containing 1 mM DTT and 1 mM PMSF. The 0.8 M-phosphate-buffer eluate was dialysed against 20 mM Tris/HCl (pH 8.0)/i mM DTT/10% glycerol/0.2M KCl/1 mM PMSF/0.I ml/I aprotinin and applied on a phosphocellulose column preequilibrated with dialysis buffer. The column was eluted consecutively with the same buffer containing 0.5 M KCl, 0.8 M KCl and 1 M KCl. Fractions eluted in 1 M KCl were verified for topoisomerase I purity by SDS/PAGE (single band at 100 kDa) and specific activity.
Purffication of PKC PKC was purified from rat brain by a modification of the method of Kikkawa et al. (1982) and Huang et al. (1986) . Briefly, seven rat brains were homogenized, centrifuged at 100000 g for 1 h, and the supernatant was applied to a DEAE-cellulose column as described by Kikkawa et al. (1982) . PKC activity was eluted at about 0.1 M NaCl when a gradient of 0-0.3 M NaCl was applied to the column. The active fractions were pooled and allowed to absorb to calcium phosphate gel [pooled volume: calcium phosphate gel slurry (17 mg/ml water) = 1:1]. The gel was washed with 20 mM potassium phosphate (pH 7.5)/0.5 mM EDTA/0.5 mM EGTA/I mM DTT/10 % glycerol/I mM PMSF, and the active enzyme was eluted with 0.2 M phosphate buffer. Buffer composition was that used for elution of PKC 304 E. Cardellini and E. Durban from hydroxyapatite as described by Huang et al. (1986) . Specific activity was 37 nmol/min per mg of protein, which is comparable with that of PKC purified to a similar extent on hydroxyapatite (Huang et al., 1986) .
Assay for PKC
The assay mixture contained 20 mM Tris/HCl, pH 7.6, 5 mM MgCl2, 40 ,ug of phosphatidylserine + 8 ,ug of diolein/ml of 0.5 mM CaCl2, 2,uCi of [y-32P]ATP (30 Ci/mmol) 25 ,1u of enzyme (0.1 unit), and 25 ,ug ofhistone HI as substrate. Reactions were allowed to proceed for 3 min at 30°C, stopped by addition of 1 ml of trichloroacetic acid (10%), and the precipitate was collected on Millipore HA filters and counted by Cerenkov radiation in a scintillation counter.
Topolsomerase I phosphorylation in vitro and tryptic cleavage Topoisomerase I eluted from phosphocellulose in 1 M KCI was directly used as substrate for PKC. The phosphorylation assay contained 5 jul of topoisomerase I (equivalent to 1 ,ug), 5 mM MgC12, phosphatidylserine (40 ,ug/ml), diolein (8 ,ug/ml), 12.5 #Ci of [y-32P]ATP (sp. radioactivity 30 Ci/mmol; 4.2 ,uM final concn.), 0.5 mM CaCl2 and 10 ul (0.04 unit) of PKC in 1O00 #1 total volume. The reaction was stopped by addition of 100 ,ul of Laemmli (1970) sample buffer, and the phosphorylation mixture was run on SDS/7.5 %-polyacrylamide gels. In order to obtain tryptic digests, gel slices containing 32P-labelled topoisomerase I were soaked in 10 % methanol for 4 h, freezedried and then incubated in 1 ml of 50 mM NH4HCO3 buffer, pH 8.0, containing 50 ,ug of trypsin [treated with tosylphenylalanylchloromethane ('TPCK'); Sigma] for 24 h at 37 'C. The supernatant was removed from the gel slices and freeze-dried as described by Durban et al. (1985) .
Topoisomerase I phosphorylation in vivo
Human HL-60 promyelocytic leukaemia cells were grown in suspension in RPMI 1640 medium/0.5 % fetal-calf serum (Gibco). For 32P labelling, cells were harvested, washed once with RPMI 1640 phosphate-free medium/0.5 % fetal-calf serum and resuspended in the same medium at 106 cells/ml. [32P]P1 was added to the cell culture at a final concentration of 0.4 mCi/ml. After incubation for 1 h at 37 'C, PMA, dissolved in dimethyl sulphoxide, was added at final concentration of 0.5 uM (to control cells, the same amount of dimethyl sulphoxide was added without PMA); incubation was continued for the times indicated. Cells were then harvested, washed once with PBS buffer (85 mM Na2HPO4/1.6 mM NaH2PO4/0.145 M NaCl, pH 7.2) and nuclei were isolated by using the same procedure used for HeLa cells. Nuclei were extracted in the triple-detergent buffer of Sambrook et al. (1989) : 50 mM Tris/HCl, pH 8.0, 50 mM NaCl, 0.02% NaN3, 0.1 % SDS, 1.0% Nonidet P-40, 0.5 % sodium deoxycholate. Each buffer used in this procedure contained 10 mM NaF and 10 mM NaHSO3 as phosphatase inhibitors, and 1 mM PMSF.
Two-dimensional gel electrophoresis
The HL-60 cell nuclear extract, diluted 1: 5 with 0.5 M Tris/HCl (pH 8.0)/i mM PMSF, was concentrated on Amicon microconcentrators (30000-Mr cut-off), washed first with 0.5 ml of distilled water containing 1 mM PMSF, and then with 1 ml of 6 M urea/0.1 % Ampholine (pH 3.5-10)/2 mM DTT/I mM PMSF and loaded on the acidic side of isoelectric-focusing SDS/4 %-polyacrylamide gels, to be subjected to twodimensional gel electrophoresis as described by Durban et al. (1981) .
Tryptic cleavage of topoisomerase I phosphorylated in vivo Gel slices, containing phosphorylated topoisomerase I, were excised from two-dimensional gels and processed as described above for topoisomerase I phosphorylated in vitro.
Two-dimensional tryptic-peptide maps Freeze-dried 32P-labelled tryptic peptides were dissolved in water, spotted on thin-layer cellulose plates (E. Merck), separated by electrophoresis in 1 % (NH4)2CO3, pH 8.9, at 500 V for 20 min and 200 V for 20 min (first dimension) and ascending chromatography (second dimension) in isobutyric acid/butan-l-ol/ pyridine/acetic acid/water (1250:38:96:58:558, by vol.) (Hunter and Sefton, 1980; Boyle et al., 1991) .
RESULTS
Topoisomerase I phosphorylation in vitro by PKC Human topoisomerase I was phosphorylated efficiently with PKC in a phospholipid/Ca2+-dependent manner (Figure 1 ). Maximal uptake was 1.6 mol of phosphate/mol of topoisomerase I in 25 min. The apparent Vmax of topoisomerase I was approx. 7-fold lower than that for histone H1 (31 pmol and 208 pmol of phosphate incorporated respectively, by using 1 unit of PKC). The apparent Km for topoisomerase I as a substrate was 1.9 ,ug/250 ,ul assay volume, or about 0.1 /M (Figure 2 ), indicating high affinity of PKC for topoisomerase I. Affinity of PKC for other protein substrates appears to be somewhat lower; the Km for good substrate peptides S6 peptide and epidermalgrowth-factor-receptor peptide was 0.5 ,uM and 1.4 ,uM respectively (House et al., 1987) . The Km for histone HI under our assay conditions was 2 ,uM, confirming the value reported previously (Kikkawa et al., 1983 (1.6 ,uM final concn.) as described in Figure 1 , except for an assay volume of 250 ul. The reaction was stopped by addition of 1 ml of 5% trichloroacetic acid/1.5% pyrophosphate, and the precipitate was collected on Millipore HA filters and counted by Cerenkov radiation. Km was evaluated from a Lineweaver-Burk plot. (results not shown), in agreement with previous results (Pommier et al., 1990) .
Topoisomerase I in HL-60 cells: phosphorylation in vivo
Exponentially growing HL-60 cells were treated with PMA for 20 min in the presence of 32P in the incubation medium. Nuclear extracts of these cells were evaluated by two-dimensional isoelectric focusing-SDS/PAGE, and phosphoproteins were detected by autoradiography (Figure 3 ). Topoisomerase I was identified by co-migration with authentic purified topoisomerase I stained by Coomassie Blue as described previously (Durban et al., 1981) . Topoisomerase I from cells treated with PMA for intensity of spots 3, 6 and 7 was noted from experiment to experiment; however, the spots identified in the Figures were reproducible. No qualitative change in phosphopeptide pattern was observed after treatment of HL-60 cells with PMA ( Figure  5 ), i.e. no additional spots were found, nor were any spots lost, after PMA treatment. Further evidence for identity of phosphopeptides labelled in vitro and in vivo was gained from two-dimensional t.l.c. tryptic maps (Figure 6 ). Some of the spots labelled in vitro were resolved into two spots in the twodimensional map, i.e. la and lb, 2c and 2d, 3e and 3f, and 4g and 4h. Spots 2c and 4g co-migrated in vitro and in vivo. Spot 3 labelled in vitro apparently co-migrated with a minor spot labelled in vivo in the one-dimensional maps (Figure 4 ). However, it is not clear if spot 3 labelled in vivo, which did not migrate in the second dimension, is present in the 'in vitro' map, due to trailing of the strongly labelled spot 3e ( Figure 6 ).
DISCUSSION
Phosphorylation of topoisomerase I increased upon treatment of HL-60 cells with PMA for 20 min. The major cellular response to PMA is activation of PKC (Castagna et al., 1982; MacFarlane, 1986; Hornbeck et al., 1988) and an increase in nuclear localization of PKC (Halsey et al., 1987; Leach et al., 1989) , which suggests that topoisomerase I phosphorylation is controlled by PKC. Comparison of phosphopeptide maps of topoisomerase I phosphorylated in HL-60 cells in vivo and by PKC in vitro does not provide unequivocal evidence for direct phosphorylation of topoisomerase I by PKC, since the major phosphopeptide found in vivo is not the major phosphopeptide in vitro. Thus increased phosphorylation of topoisomerase I in HL-60 cells in vivo may be mediated through an intermediate kinase which is under direct control of PKC. An alternative explanation may be that the conformation of topoisomerase I is different in vivo and in vitro. In vivo, topoisomerase I is loosely bound to DNA/chromatin, on the basis of its extraction properties (Durban et al., 1981) , whereas the purified protein in vitro is in the free form, and perhaps in a different conformation which may permit altered efficiency of phosphorylation at a particular site. A major site in vivo may no longer be the most accessible site for PKC phosphorylation in vitro. An increase in phosphorylation of several other nuclear proteins was observed after PMA treatment of HL-60 cells ( Figure 3 ), in agreement with observations by MacFarlane (1986) . Thus PKC may act on several nuclear proteins in a concerted fashion as part of a general regulatory pathway. In this context, it is noteworthy that DNA polymerase a is phosphorylated by PKC in vitro and stimulated 3-fold in its enzymatic activity (Krauss et al., 1987) . Recently, Samuels and Shimizu (1992) presented evidence that mouse topoisomerase I is phosphorylated by PKC in vivo. Interestingly, fundamental differences seem to exist in phosphorylation of topoisomerase I in human and mouse cell lines. Whereas our 'in vitro' map of HeLa-cell topoisomerase I is essentially in agreement with that of Samuels and Shimizu (1992) , our homologous map of human topoisomerase I labelled in vivo appears different from that of mouse topoisomerase I. Since the mouse sequence is not yet available, even minor changes in amino acid sequence could account for differences in phosphorylation sites (Durban et al., 1988 ). An important physiological difference in mouse and human cell systems was the PMA response time to reach maximal topoisomerase I phosphorylation: optimal phosphorylation was observed 20 min after PMA treatment in human HL-60 cells (Table 1) , whereas 60 min or more of PMA treatment was required in the mouse fibroblasts (Samuels and Shimizu, 1992) . This difference may relate to intrinsic physiological differences: PMA induces terminal differentiation of the human promyelocytic leukaemia cell line HL-60 (Gallagher et al., 1979; Huberman and Callaham, 1979) , whereas cultured fibroblasts undergo general mitogenic metabolic and biochemical changes in response to PMA (Rozengurt, 1986; Shimizu et al., 1986) .
In earlier studies we have shown that topoisomerase I is phosphorylated by NII kinase (casein type II kinase) in vivo and in vitro. This phosphorylation in vitro is associated with enzyme activation (Mills et al., 1982; Durban et al., 1983 Durban et al., , 1985 . Topoisomerase I activity is also increased by phosphorylation with PKC in vitro (Pommier et al., 1990) . However, the actual phosphorylation sites are different: NII kinase prefers serine/threonine in an acidic environment (Chan et al., 1986; Edelman et al., 1987) , whereas PKC prefers serine/threonine in a basic environment (House et al., 1987) . The presence of unique phosphopeptides labelled in vivo (spots 6-8) not labelled by PKC in vitro (Figure 4) suggests that topoisomerase I has multiple phosphorylation sites whose function is related to stimulation of enzymic activity and may be part of at least two different regulatory phosphorylation cascades. Whether these sites are inter-related in their regulatory function (Roach, 1991) needs to be addressed in future studies.
